골수증식성 질환 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 유형별, 약 제 유형별, 투여 경로별, 유통 채널별, 지역별, 경쟁별 세분화(2020-2030년)
Myeloproliferative Disorders Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Drug Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F
상품코드:1886295
리서치사:TechSci Research
발행일:2025년 12월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 골수증식성 질환 치료제 시장은 2024년 99억 4,000만 달러에서 2030년까지 140억 6,000만 달러로, CAGR 5.95%로 성장할 것으로 예측됩니다. 골수증식성 질환(MPD) 치료제는 골수 줄기세포의 비정상적인 증식으로 인한 만성 혈액 악성 종양군 치료에 특화된 의약품 분야입니다. 이러한 질환에서는 혈액 세포가 과도하게 생산됩니다. 시장 확대의 주요 요인은 고령화의 영향을 크게 받는 MPD의 전 세계 유병률 증가와 분자진단 기술의 발전으로 보다 빠르고 정확한 질병 식별이 가능해졌기 때문입니다.
시장 개요
예측 기간
2026-2030
시장 규모 : 2024년
99억 4,000만 달러
시장 규모 : 2030년
140억 6,000만 달러
CAGR : 2025-2030년
5.95%
가장 빠르게 성장하는 부문
JAK2 저해제
최대 시장
북미
주요 시장 성장 촉진요인
세계 골수 증식성 질환 치료제 시장은 크게 두 가지 요인, 즉 골수 증식성 질환의 유병률 증가와 새로운 치료법 연구 및 개발의 지속적인 진전에 의해 영향을 받고 있습니다. 발생률의 상승과 지속적인 관리가 필요한 환자 수 증가가 시장 확대에 크게 기여하고 있습니다.
주요 시장 과제
세계 골수증식성 질환 치료제 시장의 성장을 가로막는 가장 큰 문제는 첨단 치료에 따른 막대한 비용입니다. 이러한 경제적 장벽은 특히 의료 서비스가 부족한 지역에서 환자들이 중요한 치료를 받을 수 있는 기회를 직접적으로 제한하고, 이는 전체 시장의 성장 잠재력을 제한합니다.
주요 시장 동향
정밀의료로의 전환을 배경으로 표적치료제에 대한 관심이 높아지고 있는 것이 세계 골수증식성 질환 치료제 시장의 중요한 동향입니다. 이 접근법은 암세포의 증식과 생존에 필수적인 특정 분자 경로를 선택적으로 억제하는 약물을 개발함으로써 기존 치료법에 비해 높은 효능과 더 나은 안전성 프로파일을 제공합니다.
The Global Myeloproliferative Disorders Drugs Market will grow from USD 9.94 Billion in 2024 to USD 14.06 Billion by 2030 at a 5.95% CAGR. Myeloproliferative Disorders (MPDs) drugs comprise a specialized pharmaceutical segment focused on treating a group of chronic hematological malignancies stemming from aberrant bone marrow stem cell proliferation, leading to an overproduction of blood cells. The market's expansion is primarily propelled by the increasing global prevalence of MPDs, which is significantly influenced by an aging demographic, alongside advancements in molecular diagnostics that enable earlier and more precise disease identification.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 9.94 Billion
Market Size 2030
USD 14.06 Billion
CAGR 2025-2030
5.95%
Fastest Growing Segment
JAK2 Inhibitors
Largest Market
North America
Key Market Drivers
The Global Myeloproliferative Disorders Drugs Market is significantly influenced by two primary drivers: the increasing prevalence of myeloproliferative disorders and continuous advancements in the research and development of novel therapies. The rising incidence and growing patient populations requiring ongoing management contribute substantially to market expansion.
Key Market Challenges
A notable challenge impeding the expansion of the Global Myeloproliferative Disorders Drugs Market is the substantial cost associated with advanced therapies. This financial barrier directly limits patient access to critical treatments, particularly within underserved regions, thereby restricting the overall growth potential of the market. High treatment expenses create a significant economic burden for patients and healthcare systems alike, often resulting in delayed or foregone treatment initiation and compromised adherence.
Key Market Trends
The increasing focus on targeted therapies represents a significant trend in the Global Myeloproliferative Disorders Drugs Market, driven by the shift towards precision medicine. This approach develops drugs that selectively interfere with specific molecular pathways crucial for the growth and survival of cancer cells, thereby offering enhanced efficacy and a more favorable safety profile compared to conventional treatments.
Key Market Players
AbbVie, Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
AstraZeneca PLC
Johnson and Johnson Services, Inc.
Sun Pharmaceutical Industries Ltd.
Hikma Pharmaceuticals PLC
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
GlaxoSmithKline plc
Report Scope:
In this report, the Global Myeloproliferative Disorders Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Myeloproliferative Disorders Drugs Market, By Type:
Primary Myelofibrosis
Polycythemia Vera
Essential Thrombocythemia
Hyper eosinophilic Syndrome
Systemic Masto cytosis
Myeloproliferative Disorders Drugs Market, By Drug Type:
JAK2 Inhibitors
Anti-Neoplastics
Demethylation Agents
Imatinib Mesylate
Others
Myeloproliferative Disorders Drugs Market, By Route of Administration:
Oral
Parental
Others
Myeloproliferative Disorders Drugs Market, By Distribution Channel:
Hospital Pharmacy
Retail Stores
Drug Stores
Myeloproliferative Disorders Drugs Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Myeloproliferative Disorders Drugs Market.
Available Customizations:
Global Myeloproliferative Disorders Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Myeloproliferative Disorders Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Hyper eosinophilic Syndrome, Systemic Masto cytosis)
5.2.2. By Drug Type (JAK2 Inhibitors, Anti-Neoplastics, Demethylation Agents, Imatinib Mesylate, Others)
5.2.3. By Route of Administration (Oral, Parental, Others)
5.2.4. By Distribution Channel (Hospital Pharmacy, Retail Stores, Drug Stores)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. North America Myeloproliferative Disorders Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Drug Type
6.2.3. By Route of Administration
6.2.4. By Distribution Channel
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Myeloproliferative Disorders Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Drug Type
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Distribution Channel
6.3.2. Canada Myeloproliferative Disorders Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Drug Type
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Distribution Channel
6.3.3. Mexico Myeloproliferative Disorders Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Drug Type
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Distribution Channel
7. Europe Myeloproliferative Disorders Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Drug Type
7.2.3. By Route of Administration
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Myeloproliferative Disorders Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Drug Type
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. France Myeloproliferative Disorders Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Drug Type
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. United Kingdom Myeloproliferative Disorders Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Drug Type
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel
7.3.4. Italy Myeloproliferative Disorders Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Drug Type
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By Distribution Channel
7.3.5. Spain Myeloproliferative Disorders Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Drug Type
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By Distribution Channel
8. Asia Pacific Myeloproliferative Disorders Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Drug Type
8.2.3. By Route of Administration
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Myeloproliferative Disorders Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Drug Type
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. India Myeloproliferative Disorders Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Drug Type
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. Japan Myeloproliferative Disorders Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Drug Type
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel
8.3.4. South Korea Myeloproliferative Disorders Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Drug Type
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Distribution Channel
8.3.5. Australia Myeloproliferative Disorders Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Drug Type
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Distribution Channel
9. Middle East & Africa Myeloproliferative Disorders Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Drug Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Myeloproliferative Disorders Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Drug Type
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.2. UAE Myeloproliferative Disorders Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Drug Type
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.3. South Africa Myeloproliferative Disorders Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Drug Type
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
10. South America Myeloproliferative Disorders Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Drug Type
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Myeloproliferative Disorders Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Drug Type
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Distribution Channel
10.3.2. Colombia Myeloproliferative Disorders Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Drug Type
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Distribution Channel
10.3.3. Argentina Myeloproliferative Disorders Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Drug Type
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Myeloproliferative Disorders Drugs Market: SWOT Analysis
